# A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma

> **NCT01169298** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 13 (actual)

## Conditions studied

- Adult T-cell Leukemia-Lymphoma
- Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT01169298
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07-01
- **Primary completion:** 2013-12-01
- **Final completion:** 2013-12-20
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2019-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01169298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01169298, "A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT01169298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*